Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G.
Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued.
| CLINICAL INDICATION | INFECTING ORGANISM | |
|---|---|---|
Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis | Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) | |
Anthrax | Bacillus anthracis | |
Actinomycosis (cervico-facial disease and thoracic and abdominal disease) | Actinomyces israelii | |
Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) | Clostridium species | |
Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) | Corynebacterium diphtheriae | |
Erysipelothrix endocarditis | Erysipelothrix rhusiopathiae | |
Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) | Fusobacterium species and spirochetes | |
Listeria infections including meningitis and endocarditis | Listeria monocytogenes | |
Pasteurella infections including bacteremia and meningitis | Pasteurella multocida | |
Haverhill fever | Streptobacillus moniliformis | |
Rat bite fever | Spirillum minus or Streptobacillus moniliformis | |
Disseminated gonococcal infections | Neisseria gonorrhoeae (Penicillin-susceptible) | |
Syphilis (congenital and neurosyphilis) | Treponema pallidum | |
Meningococcal meningitis and/or septicemia | Neisseria meningitidis | |
Gram-negative bacillary infections (bacteremias) | Gram-negative bacillary organisms (i.e. Enterobacteriaceae) |
To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium and other antibacterial drugs, Penicillin G Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G.
Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued.
| CLINICAL INDICATION | INFECTING ORGANISM | |
|---|---|---|
Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis | Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) | |
Anthrax | Bacillus anthracis | |
Actinomycosis (cervico-facial disease and thoracic and abdominal disease) | Actinomyces israelii | |
Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) | Clostridium species | |
Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) | Corynebacterium diphtheriae | |
Erysipelothrix endocarditis | Erysipelothrix rhusiopathiae | |
Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) | Fusobacterium species and spirochetes | |
Listeria infections including meningitis and endocarditis | Listeria monocytogenes | |
Pasteurella infections including bacteremia and meningitis | Pasteurella multocida | |
Haverhill fever | Streptobacillus moniliformis | |
Rat bite fever | Spirillum minus or Streptobacillus moniliformis | |
Disseminated gonococcal infections | Neisseria gonorrhoeae (Penicillin-susceptible) | |
Syphilis (congenital and neurosyphilis) | Treponema pallidum | |
Meningococcal meningitis and/or septicemia | Neisseria meningitidis | |
Gram-negative bacillary infections (bacteremias) | Gram-negative bacillary organisms (i.e. Enterobacteriaceae) |
To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium and other antibacterial drugs, Penicillin G Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.